Loading stock data…
AGIO
$28.16+0.16 (+0.57%)
Market ClosedLast close May 1
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Agios Pharmaceuticals, Inc. in the Healthcare sector is trading at $28.16. The stock is currently 39% below its 52-week high of $46.00, remaining 15.2% below its 200-day moving average. Technical signals show neutral RSI of 36 and bearish MACD signal, explaining why AGIO maintains its current current market pressure. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 36) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$28.16
Potential Upside
5%
Whystock Fair Value$29.57
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus8 analysts
Buy
Mean target$41.13+46.0%
Range$28.00 – $60.00
Fundamentals
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.67B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.79
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-34.60%
Volume
Today's trading volume
1.14M
Recent News
AGIO Beats on Q1 Earnings & Sales, Stock Up 13% on New Drug Momentum
Agios shares jump 13% as Q1 revenues surge 138% on Aqvesme launch and Pyrukynd growth, while pipeline advances and SCD filing plans take shape.
Agios Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary
Moby summary of Agios Pharmaceuticals, Inc.'s Q1 2026 earnings call
Why Agios Pharmaceuticals Stock Zoomed to a 13% Gain on Wednesday
There's power in the company's No. 1 molecule.
Agios Pharmaceuticals Q1 Earnings Call Highlights
Agios Pharmaceuticals (NASDAQ:AGIO) reported first-quarter 2026 worldwide mitapivat net revenues of $20.7 million and highlighted early traction from the U.S. launch of AQVESME in thalassemia, alongside progress toward a potential U.S. Accelerated Approval filing for mitapivat in sickle cell disease
Agios Pharmaceuticals (AGIO) Reports Q1 Loss, Tops Revenue Estimates
Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of +6.72% and +50.44%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?